Gri bio reports second quarter 2024 financial results and provides corporate update

Company focused on execution of lead program gri-0621 for the treatment of idiopathic pulmonary fibrosis (ipf) gri-0621 interim data readout of phase 2a biomarker study on track for q4 2024 and topline data on track for q1 2025 la jolla, ca, aug. 14, 2024 (globe newswire) -- gri bio, inc. (nasdaq: gri) (“gri bio” or the “company”), a biotechnology company advancing an innovative pipeline of natural killer t (nkt) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported its financial results for the second quarter ended june 30, 2024 and provided a corporate update. “our focus and priority remain on the successful execution of our phase 2a biomarker study of gri-0621 for the treatment of ipf, with interim data by the end of the year and topline data on track for q1 2025.
GRI Ratings Summary
GRI Quant Ranking